0001209191-17-006370.txt : 20170131 0001209191-17-006370.hdr.sgml : 20170131 20170131162447 ACCESSION NUMBER: 0001209191-17-006370 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170130 FILED AS OF DATE: 20170131 DATE AS OF CHANGE: 20170131 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CELGENE CORP /DE/ CENTRAL INDEX KEY: 0000816284 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222711928 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 BUSINESS PHONE: (908)673-9000 MAIL ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PEHL MICHAEL F. CENTRAL INDEX KEY: 0001677939 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34912 FILM NUMBER: 17561439 MAIL ADDRESS: STREET 1: C/O CELGENE CORPORATION STREET 2: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-01-30 0 0000816284 CELGENE CORP /DE/ CELG 0001677939 PEHL MICHAEL F. C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901 0 1 0 0 See remarks Stock Option (right to buy) 113.18 2017-01-30 4 A 0 5000 A 2027-01-30 Common Stock 5000 5000 D Option is immediately exercisable and will vest in four equal annual installments commencing on January 30, 2018. The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). President, Hematology & Oncology /s/ Peter N. Kellogg, Attorney-in-Fact 2017-01-31